Table 3 Mean TCS, DSS, and DMS during the peak season and the entire season in the Canadian subgroup
Peak season | Entire season | |||||
|---|---|---|---|---|---|---|
6 Amb a 1-U MK-3641 (n = 87) | 12 Amb a 1-U MK-3641 (n = 94) | Placebo (n = 104) | 6 Amb a 1-U MK-3641 (n = 88) | 12 Amb a 1-U MK-3641 (n = 94) | Placebo (n = 104) | |
TCS | 7.03 | 5.74 | 9.49 | 6.06 | 4.91 | 7.82 |
Difference vs placebo (95% CI) | -2.46 (-3.90, -1.02) | -3.75 (-5.16, -2.34) | -1.75 (-2.93, -0.58) | -2.91 (-4.07, -1.75) | ||
p value | .0009 | < .0001 | .0036 | < .0001 | ||
Reduction vs placebo | 25.95% | 39.52% | 22.44% | 37.23% | ||
DSS | 5.09 | 4.44 | 5.95 | 4.51 | 3.91 | 5.05 |
Difference vs placebo (95% CI) | -.86 (-1.78, .06) | -1.52 (-2.42, -.61) | -.54 (-1.33, .24) | -1.14 (-1.92, -.37) | ||
p value | .0677 | .0011 | .1746 | .0038 | ||
Reduction vs placebo | 14.46% | 25.49% | 10.72% | 22.66% | ||
DMS | 1.93 | 1.30 | 3.53 | 1.55 | 1.00 | 2.77 |
Difference vs placebo (95% CI) | -1.60 (-2.36, -.84) | -2.23 (-2.97, -1.49) | -1.21 (-1.81, -.61) | -1.77 (-2.35, -1.18) | ||
p value | < .0001 | < .0001 | < .0001 | < .0001 | ||
Reduction vs placebo | 45.29% | 63.14% | 43.82% | 63.84% | ||